Your Health, We Care
Release date: 2026-03-25 13:54:05 Article From: Lucius Laos Recommended: 95
Pirtobrutinib is a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor developed by Eli Lilly in the United States. It was first approved by the U.S. FDA on January 27, 2023, for the treatment of relapsed or refractory mantle cell lymphoma in adults. Subsequently, on December 1, 2023, it was approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in adults who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Pirtobrutinib is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma who have previously received treatment with a covalent BTK inhibitor.
Indicated for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a BTK inhibitor.
Pirtobrutinib is the first non-covalent (reversible) BTK inhibitor approved by the FDA. It can re-establish BTK inhibition in patients previously treated with covalent BTK inhibitors (ibrutinib, acalabrutinib, or zanubrutinib) and expand the benefits of targeted BTK pathway therapy.
Mantle cell lymphoma is a rare blood cancer and a form of non-Hodgkin lymphoma. It arises in B lymphocytes, a type of white blood cell that is part of the immune system. Mantle cell lymphoma typically originates in B cells located in the outer mantle zone of lymph nodes. As the cancer progresses, it can spread to the bone marrow, spleen, liver, or digestive tract.
Chronic lymphocytic leukemia and small lymphocytic lymphoma are slow-growing non-Hodgkin lymphomas that develop from white blood cells called lymphocytes. Chronic lymphocytic leukemia is one of the most common types of leukemia in adults. From a pathological and immunophenotypic perspective, small lymphocytic lymphoma is identical to chronic lymphocytic leukemia, with the main difference being the location of the cancer cells. In chronic lymphocytic leukemia, cancer cells are present in the blood, whereas in small lymphocytic lymphoma, they are found in the lymph nodes.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3492025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3502025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：3002025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
